Showing 12 posts of 12 posts found.


GSK sets up new CRISPR lab with UC, Berkeley

June 13, 2019
Medical Communications GSK, UC, berkely, crispr, genetics, pharma

GSK has struck a $67 million deal with the University of California, Berkeley. British multinational GlaxoSmithKline will collaborate with UC, …

Doctors treat porphyria using innovative gene silencing drug

April 15, 2019
Sales and Marketing RNA, gene silencing, genetics, givosiran, health, porphyria

Doctors have successfully treated porphyria using an innovative ‘gene-silencing’ drug. Speaking to the BBC, Professor David Rees, from King’s College …

Researchers use CRISPR to reveal gene targets in 30 types of cancer

April 11, 2019
Research and Development Cancer, crispr, drug development, genes, genetics, oncology

Researchers at the Wellcome Sanger Institute and Open Targets have been able to identify thousands of genes which play a …

23andMe to offer genetic reports on diabetes

March 11, 2019
Sales and Marketing 23andME, Genentech, GlaxoSmithKline, Lundbeck, diabetes, genetics, genomics

Personal genomics company, 23andMe will offer customers information on the likelihood that they are genetically predisposed to developing type 2 …

Researchers activate gene to reverse depression in mice

February 18, 2019
Sales and Marketing SIRT1, depression, genetics, mental health

Scientists at the Medical College of Georgia at Augusta University were able to directly activate a gene associated with depression …


Widening the focus on innovations in cancer treatment

September 3, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 23andME, CRUK, Cancer, GSK, diagnosis, genetics, oncology, pharma

Cancer treatment is making leaps and bounds, but public focus tends to gravitate towards the therapies themselves. Matt Fellows explores …


GSK forges $300m partnership with 23andMe to boost preclinical R&D

July 26, 2018
Research and Development 23andME, GSK, GlaxoSmithKline, collaboration, genetics, pharma

In a bid to supercharge its drug discovery efforts, GlaxoSmithKline has sealed a $300 million deal with personal genomics and …


Amgen’s denosumab may help check breast cancer in women with BRCA1 gene – Study

June 21, 2016
Manufacturing and Production, Research and Development Amgen, Prolia, Xgeva, biotech, breast cancer, drug trial, genetics

US biotech firm Amgen’s (Nasdaq: AMGN) Prolia (denosumab) to treat osteoporosis and Xgeva to prevent fractures in cancer patients, may …


Regeneron agrees six-year $75 million upfront licencing deal with Intellia for gene technology

April 12, 2016
Manufacturing and Production, Research and Development, Sales and Marketing IPO, Intellia Therapeutics, Licencing, Regeneron Pharmaceuticals, crispr, deal, gene editing, genetics

Regeneron Pharmaceuticals Inc (Nasdaq: REGN) on Tuesday said it has signed a six-year licencing deal with biotech firm Intellia Therapeutics …


GW Pharma starts Phase III trials for Tuberous Sclerosis Complex drug

April 11, 2016
Research and Development Epidiolex, GW Pharmaceuticals, Tuberous Sclerosis Complex, genetics, rare disease

GW Pharmaceuticals Plc (Nasdaq: GWPH) said it has started late-stage trials for its Epidiolex (cannabidiol or CBD) to treat seizures …

23andMe’s apps to aid genetic research for Apple’s ResearchKit

March 22, 2016
Manufacturing and Production, Research and Development 23andME, Apple, genetics, research

Privately-held 23andMe has announced a new module for Apple’s (Nasdaq: AAPL) open source ResearchKit software framework that allows scientists to …

23andme logo

23andMe targets $150 million for drug development

July 8, 2015
Research and Development 23andME, DNA, DNA testing, genetics, venture capital

The genetic testing firm 23andMe is seeking to raise $150 million in order to move into its own drug development …

Latest content